.svg){kind=small}
Where to Buy
Beneleaves is stocked at 117 licensed dispensaries across Ohio, with the deepest coverage in Columbus, Cincinnati, Cleveland, Lorain, and Dayton. Search by ZIP code or city below to find the closest one, or filter by product type if you are after a specific format.
Market Insights Snapshot
Beneleaves concentrated 89.56% of July 2026 sales in Capsules, with that category up 745.95% year over year and 16.10% month over month, while Edible held 2.85% share with a 668.20% year-over-year surge and a 75.87% month-over-month jump. Topical accounted for 5.86% share with 7.81% YoY growth and 2.45% MoM growth, whereas Vapor Pens slipped to 1.73% share with a -43.83% YoY decline and a -16.86% MoM drop; combined with an average price decline of -14.74% YoY to $27.59, the mix skews toward lower-priced Capsules that are scaling volume quickly. The pattern implies Beneleaves is consolidating around Capsules leadership while selectively nurturing Edible as a fast-rising secondary pillar, and de-emphasizing Vapor Pens to avoid margin drag.
With Capsules ranked 1 in the category in Ohio and growing 16.10% MoM alongside a 668.20% YoY surge in Edible, the portfolio tilts toward formats that benefit from repeatable dosing and price-accessible entry points. The -43.83% YoY contraction in Vapor Pens paired with only 2.45% MoM growth in Topical signals a pivot away from impulse-oriented inhalables toward regimented wellness use cases; given total brand sales up 413.63% YoY and average price down -14.74% YoY, the positioning trend implies scale via Capsules dominance with Edible expansion as the next demand lever while maintaining Topical as a stability anchor.
Competitive Landscape
Beneleaves holds #1 in OH Capsules in July 2026 after rising 4 positions year over year from #5, and it maintained #1 over the last three months while matching its peak rank of #1 in July 2026; meanwhile, UB GOOD sits at #2 after improving from #3 with 31.4% YoY sales growth, and Main Street Health slid from #2 to #3 with a 15.9% YoY sales decline, indicating Beneleaves’ move from #5 to #1 is less about short-term volatility and more about sustained outpacing of rivals who are either advancing more slowly or contracting.
Notable Products
Hybrid RSO Capsules 11-Pack (550mg) posted the largest movement in July 2026 with a 103.2% month-over-month surge, yet it sat at rank 6 while RSO Capsules 22-Pack (660mg) held rank 1 with an 11.6% lift; this gap indicates momentum is building in mid-tier potency without displacing the flagship. THC/CBG 1:1 Sativa Helios Capsules 22-Pack (220mg THC, 220mg CBG) declined 20.3% MoM at rank 7, while Sativa Helios Capsules 11-Pack (440mg) advanced 23.1% at rank 3, signaling a shift from 1:1 formulations toward single-dominant or higher-potency SKUs. With nine of the top ten coming from Capsules and only one Topical at rank 10 falling 16.5% MoM on $10,889, the assortment is concentrating around ingestible formats as value and potency tiers segment the basket.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
